Therapeutic plasmapheresis and experience in Alzheimer's disease;Plasmaféresis terapéutica y experiencia en la enfermedad de Alzheimer

Revista de Neurologia

Volumn 50, Issue SUPPL. 5, 2010, Pages

  Anaya, Fernando ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Albumin; Alzheimer's disease; Plasma exchange; Plasmapheresis; Therapeutic apheresis

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; GRIFOLS; HUMAN ALBUMIN; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; COGNITIVE DEFECT; FEASIBILITY STUDY; HUMAN; PLASMAPHERESIS;

ALBUMINS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; PLASMAPHERESIS;

EID: 77953564297     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Anaya F. Consideraciones técnicas. In Anaya F, ed. Aféresis terapéutica. Madrid: Capitel Ediciones; 2005. p. 7-20.
2. Anaya F, Lomana F. Procedimientos aferéticos. In Anaya F, ed. Aféresis terapéutica. Madrid: Capitel Ediciones; 2005. p. 21-33.
3. Anaya F, Mayayo M, Pintado T, Gómez-Pineda A, Buño I, Anguita J, et al. Indicaciones. In Anaya F, ed. Aféresis terapéutica. Madrid: Capitel Ediciones; 2005. p. 67-306.
4. Bosch T, Gahr S, Belschner U, Schaefer C, Lennertz A, Rammo J. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions. Ther Apher Dial 2006; 10: 210-8.
5. Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial 2003; 7: 382-90.
6. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
7. Wimo A, Winblad B, Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007; 3: 81-91.
8. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
9. Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, et al. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21: 43-53.
10. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
11. Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-13.
12. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-34.
13. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271: 32916-22.
14. Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, et al. Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 2009; 22: 325-39.